On a mission to save Teva from crippling debt, Schultz stands by cost-cutting measures, scrutinizes per product profitability
SAN FRANCISCO — Kåre Schultz didn’t mince words at Teva’s JPM presentation this morning, launching his talk by outlining the company’s colossal challenges in the years ahead.
The elephant in the room? The company’s $32 billion in debt and massive cuts. Schultz’ candid delivery earned a few laughs from the audience, as he pointedly skipped the sugar-coated rhetoric often present onstage at JPM.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.